FDA committee OKs Amgen’s Evenity

A U.S. Food and Drug Administration advisory committee voted in favor of a new approval for Amgen’s osteoporosis treatment Evenity for use by postmenopausal women. The Bone, Reproductive and Urologic Drugs Advisory Committee voted to approve the expanded use of the treatment following the release of new safety and efficacy data and emphasized the need Read More →
Read More →
MannKind launches direct-purchase program for its inhalable insulin

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Amgen’s patent-related legal disputes resolved

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Atara CEO departing, company pivots toward new leadership

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Despite a recent $105 million contract, Mannkind files for yet another public offering

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Amgen donations to CSUCI developing STEM ecosystem

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →